Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-04-26
2011-04-26
Kosar, Andrew D (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S314000
Reexamination Certificate
active
07932228
ABSTRACT:
Provided is a method for the use of a bradykinin B1 receptor antagonist of formula I: X-CO-Aaa0-Aaa1-Aaa2-Aaa3-Gly-α(Me)Phe-Ser-D-βNal-Aaa8-OH (I) or a pharmaceutically acceptable salt or hydrate thereof wherein: X is CnH2n+1or CiH2i—C6H5, where n is an integer from 1 to 3, and i is an integer from 0 to 3; Aaa0is Lys, Orn or Cit; Aaa1is Arg or Cit, and preferably Arg; Aaa2is Oic, Hyp or Pro, and preferably Oic; Aaa3is Pro or Oic, and preferably Pro; and Aaa8is Ile, Leu or Nle, and preferably Ile, for the treatment of metastases, cancers and/or chemotherapy-induced neuropathies, comprising the administration of the compound to a patient in need of such treatment. Also provided are compositions containing such antagonists and their thereof.
REFERENCES:
patent: 5610140 (1997-03-01), Goodfellow et al.
patent: 5635593 (1997-06-01), Cheronis et al.
patent: 5700779 (1997-12-01), Goodfellow et al.
patent: 5750506 (1998-05-01), Goodfellow et al.
patent: 5834431 (1998-11-01), Stewart et al.
patent: 5843900 (1998-12-01), Cheronis et al.
patent: 5849863 (1998-12-01), Stewart et al.
patent: 5863899 (1999-01-01), Cheronis et al.
patent: 5935932 (1999-08-01), Stewart
patent: 6075120 (2000-06-01), Cheronis et al.
patent: 7041785 (2006-05-01), Regoli et al.
patent: 7211566 (2007-05-01), Regoli et al.
patent: 2004/0198666 (2004-10-01), Regoli et al.
patent: 97/09346 (1997-03-01), None
patent: 98/07746 (1998-02-01), None
patent: 99/64039 (1999-12-01), None
Authier et al., Experimental Neurology, 2003, 182:12-20.
Calixto et al., Brit. J. Pharmacol., 2004, 143(7):803-818.
Gabra et al., European Journal of Pharmacology, 2002, 457:115-124.
Galoppini et al., Journal of Medicinal Chemistry, 1999, 42:409-414.
Gama Landgraf et al., Inflammation Research, 2004, 53:78-83.
Gaudreau et al., Canadian Journal of Physiology & Pharmacology, 1981, 59:371-379.
Gobeil et al., Br. J. Pharmacol., 1996, 118: 289-294.
Gobeil et al., Hypertension, 1999. 33:823-829.
Gobeil et al., Canadian Journal of Physiology & Pharmacology, 1997, 75:591-595.
Leeb-Lundberg et al., Pharmacological Reviews, 2005, 57:27-77.
MacNeil et al., Canadian Journal of Physiology & Pharmacology, 1997, 75:735-740.
Neugebauer et al., Canadian Journal of Physiology & Pharmacology, 2002, 80:287-292.
Ocean et al., Support Care Cancer, 2004, 12:619-625.
Stewart et al., Immunopharmacology, 1997, 36:167-172.
Stewart, Current Pharmacological Design, 2003, 9:2036-2042.
Taub et al., Cancer Research, 2003, 63:2037-2041.
Battistini Bruno Joseph
Chammas Roger
Nantel François
Sirois Pierre
Kosar Andrew D
Nixon & Peabody LLP
Societe de Commercialisation des Produits de la Recherche Appliq
LandOfFree
Method of treating bone or prostate cancer with selective... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating bone or prostate cancer with selective..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating bone or prostate cancer with selective... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2665189